Kornimate/medical-research-clean huggingface dataset:
engaging men from blue-collar industries in weight loss

Conditions: Obesity

Summary: objectives\*: primary objective: aim 1: examine the acceptability of tailored behavioral weight loss program and a standard program in men working in blue-collar occupations. aim 2: compare recruitment approaches that vary on trust-based messaging to recruit men with overweight/obesity who work in blue-collar occupations. secondary objectives: determine the feasibility of retaining participants to a randomized trial over six months.

men working in blue-collar occupations have a high prevalence of overweight and obesity and have high rates of comorbidities associated with obesity. unfortunately, these men are unlikely to participate in evidenced-based weight loss interventions. further, few efficacious interventions have been developed that target this population for weight control. the purpose of this study is to test the feasibility and acceptability of tailored recruitment messages and a novel, tailored behavioral weight loss intervention in the context of a randomized trial.

Eligibility criteria:
inclusion criteria: 1. age 18 years and older 2. male 3. body mass index (bmi) \> 25 kg/m2 4. employed \>20 hours per week in an occupation classified as blue collar 5. ability to communicate in english 6. provision of signed and dated informed consent form exclusion criteria: 1. history of bariatric surgery 2. diabetes managed with insulin 3. diagnosis of a serious mental illness 4. conditions contraindicated to exercise independently (determined using four questions of physical activity readiness questionnaire) 5. report of potentially hazardous alcohol use (assist \>27) 6. weight loss in the prior six months of 10 pounds or greater 7. body mass index ≥60 kg/m2, due to increased injury risk with exercise 8. diagnosis of an eating disorder 9. any major medical condition that could increase risk for injury or other contradictions for treatment, or high likelihood of attrition, as determined by the study team

Keywords: occupation behavioral treatment
multiple ascending doses of medi6012 in subjects with stable atherosclerotic cardiovascular disease

Conditions: Atherosclerosis; Cardiovascular Disease

Summary: to evaluate the safety pharmacokinetics, and pharmacodynamics of repeat weekly dosing of medi6012 in subjects with stable atherosclerosis.

a phase 2a randomized, blinded, placebo-controlled study to evaluate the safety, pharmacokinetics and pharmacodynamics of multiple ascending doses of medi6012 in subjects with stable atherosclerotic cardiovascular disease

Eligibility criteria:
inclusion criteria: * non-childbearing potential * diagnosis of stable atherosclerotic cvd * currently receiving a stable dose of statin exclusion criteria: * unstable cardiovascular condition within 3 months of screening * elective arterial revascularization with in the past month * any planned arterial revascularization * body mass index \ 45 * clinically significant ecg that may interfere with the interpretation of serial ecg and qt interval changes at screening * chronic kidney disease defined by estimated glomerular filtration rate of less than 30 ml/mim/1.73m2 * triglycerides greater than 500 mg/dl, ldl-c greater than 160 mg/dl, or hdl-c greater than 60 for males, or 65 for females * clinically significant vital sign abnormalities * genetic disorder of cholesterol metabolism * history of overt liver disease * poorly controlled endocrine disorder (diabetes or thyroid disorder) * current or recent use of systemic corticosteroids * recent or ongoing infection or febrile illness * history of active malignancy within 5 years * history of alcohol or recreational substance abuse in the past 6 months * concurrent enrollment in another clinical study of any investigational drug therapy or use of any biologicals within 6 months prior to screening or within 5 half-lives of an investigational agent or biologic, whichever is longer.

Keywords: atherosclerosis cardiovascular disease cad atherosclerotic cardiovascular disease
oral cavity squamous cell carcinoma and readmission: rates, causes, and risk factors.

Conditions: Oral Cavity Squamous Cell Carcinoma; Readmission

Summary: we sought to comprehend the rates and causes of unplanned hospital readmission within 60 days following oral cancer surgery


Eligibility criteria:
inclusion criteria: * all patient underwent oral cancer surgery in king abdulaziz university hospital exclusion criteria: * significant missing data
dcbti with and without coaching support

Conditions: Insomnia

Summary: the current research aims to evaluate the adherence and efficacy of dcbti with different types of coaching support.

participants will be randomly assigned to one of the five conditions. c1: sleep hygiene and self-monitoring control condition; c2: dcbti without coaching; c3; dcbti with virtual coaching; c4: dcbti with non-therapist coaching; c5: dcbti with therapist coaching. question 1: does dcbti work better than the active control? hypothesis 1: participants in c2, c3, c4, and c5 will have greater improvement in insomnia than those in c1. question 2: does coaching support, virtual or human, improve treatment adherence and outcome? hypothesis 2: participants in c3, c4, and c5 will have greater improvement in insomnia and greater adherence to treatment recommendations than those in c2. question 3: does human coaching enhance treatment adherence and outcome? hypothesis 3: participants in c4 and c5 will have greater improvement in primary outcome than those in c3. question 4: does therapist-coaching-support enhance treatment adherence and outcome to a greater extent than virtual and non-therapist coaching support? hypothesis 4: participants in c5 will have greater improvement in primary outcome than those in c3 and c4.

Eligibility criteria:
inclusion criteria: * (a) hong kong resident, * (b) aged 18 or above, * (c) able to read and write chinese, * (d) has regular access to a smart phone and internet, * (e) insomnia severity index ⩾10; * (f) willing and can be contacted by experimenter via phone between 9 am - 9 pm exclusion criteria: * (a) significant untreated/unstable mental or medical illness, * (b) known factor to interfere with participation in this research, * (c) serious medical, neurological, or psychiatric illness that may affect participation in this research, * (d) sleep apnea, * (e) concurrent treatment for insomnia, * (f) unstablized medication that can affect sleep

Keywords: digital intervention cognitive behavioral therapy for insomnia treatment efficacy treatment adherence
the effect of midazolam on dexamethasone-induced perineal pruritus

Conditions: Pruritus

Summary: dexamethasone is commonly used in clinical practice.however, intravenous dexamethasone sodium phosphate may cause perineal discomfort.with the popularization of comfortable medical technology, patients have higher and higher requirements for comfortable medical treatment.perineal pruritus caused by intravenous dexamethasone sodium phosphate may cause adverse physiological and psychological effects on patients and increase the incidence of unpleasant experiences during anesthesia.therefore, it is very important to find a practical and effective method of inhibition.midazolam is a water-soluble benzodiazepine commonly used in clinical practice, which has been proved to effectively inhibit the itching caused , while its effect on the itching caused by dexamethasone has not been reported.by observing the effect of pre-injection midazolam on the perineal itching caused by dexamethasone sodium phosphate, this experiment intends to preliminarily explore its possible mechanism .

nighty patients scheduled for selective surgery,aged 18-65years,asa physical status i\~ii,bmi 18\~30kg·m-2 were selected in this study.the patients were equally randomized into two groups: midazolam (m) group and normal saline (n) group, 45 cases in each group. before anesthesia induction, m group received intravenous injection of 0.03mg·kg-1 (1mg·ml-1) midazolam, while n group received corresponding intravenous normal saline of the same volume. after 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg (injection was completed in 2s). the anesthesiologist assessed perineal irritation in both groups and recorded the number of cases,visual analogue scores (vas) ,duration of itching or pain,ramsay scores and observed the occurrence of adverse reactions such as dizziness and respiratory depression in the two groups.

Eligibility criteria:
inclusion criteria: the undergoing elective surgery patients, ages 18 to 65 years, asa ⅰ or ⅱ level, body mass index (bmi) of 18 \~ 30 kg · m-2. exclusion criteria: diabetes mellitus, paresthesia, allergy to narcotic drugs, routine preoperative use of narcotic analgesics, long-term use of hormones, drug and alcohol abuse, communication disorders in psychiatric disorders, pregnancy or lactation, and patients with severe systemic diseases and unwilling to undergo the trial.

Keywords: midazolam; dexamethasone; pruritus
neural mobilization and conventional physical therapy after laminectomy

Conditions: Laminectomy

Summary: this study was conducted to evaluate the effect of addition of neural mobilization to a standard post-operative physical therapy program in patients with lumbar laminectomy.

after laminectomy, patients are suffering from many problems as pain, weakness. this study was conducted on two groups of patients who underwent lumbar laminectomy as a surgical treatment for lumbar canal stenosis. the control group received tens and strengthening exercises, while the study group received neural mobilization in addition to the program that was given to the control group. the outcome measures include pain intensity, nerve root compression and functional level which were measured pre-treatment and post-treatment through using visual analogue scale, h-reflex latency and oswestry disability index (odi) respectively.

Eligibility criteria:
inclusion criteria: * aged from 35-50 years. * underwent lumbar laminectomy of one or two levels. exclusion criteria: * patients who had arthritis in the joints of the lower limbs (which would limit walking). * patients who had tumors, fractures or infections of the spine. * patients who had diabetes mellitus. * patients who had polyneuropathy. * patients who had evidence of spinal cord compression. * patients who had previous spinal surgery. * patients who had spinal stability problems (e.g. spondilo-listhesis, spondilolysis). * patients who had sensory loss.
analysis of the acceptance and changes to parameters programming suggested by the therapyguide function

Conditions: Bradyarrhythmia

Summary: the technological progress allowed the development of more and more sophisticated pacemakers, widening the therapeutic indications but also meeting the physiological needs of the patient. this progress led to a more and more complex programming for the physicians. to help them set optimally the pacing parameters, physicians refer to the existing recommendations of learned societies as well as to his expertise. manufacturers developed also algorithms integrated into pacemakers with the aim of assisting physicians in their programming. therapyguide is a function which proposes a programming adapted to the psychopathological state of the patient, with a justification based on experts' consensus, clinical studies as well as on published articles. physicians have the choice to accept or reject the programming proposed by therapyguide. when rejected, there is no means to analyze the modifications brought to the proposed set of parameters. the nature, the frequency and the reasons of these modifications are not thus known. the purpose of this study is to assess the acceptance of the therapyguide proposals by physicians and to identify the most frequent type of programming changes they make and their rationale.


Eligibility criteria:
inclusion criteria: * patient implanted with a pacemaker featuring the therapyguide function * patient more than 18 years of age. * patient able to sign a data release authorization form exclusion criteria: - unwillingness or inability to provide written consent

Keywords: pacemaker programming bradyarrhythmia
clinical implication of 3-vessel fractional flow reserve (ffr)

Conditions: Multivessel Coronary Artery Disease

Summary: this study will evaluate the influence of total atherosclerotic burden assessed by 3-vessel fractional flow reserve (ffr) on the clinical outcomes of the patients with multi-vessel disease. for this purpose, the clinical data of the patients with 3-vessel intermediate coronary artery disease, whose ffr was measured at all 3-vessels due to their own clinical needs, will be analyzed.

primary analysis the primary analysis will be performed after 2-year follow-up data will be completed. pre-specified subgroup analysis the pre-specified subgroup analysis will perform after 1-year follow-up data will be completed according to the following subjects: * concordant and discordant results between ffr and angiographic stenosis severity (patients and lesions with pre-pci ffr will be analyzed.). * association between total atherosclerotic burden and total ischemic burden, coronary ct angiography substudy (after 2-year follow-up will be completed). * validation of total ischemic burden (sum of 3 vessel ffr) with duke score, measured by treadmill test. * comparison of clinical outcomes of deferred lesions according to pre-pci ffr levels (pre-pci ffr \ 0.80). * comparison of clinical outcomes of deferred lesions according to ifr and ffr values ⑥ prognosis of functional complete revascularization versus incomplete revascularization

Eligibility criteria:
inclusion criteria: * subject must be at least 18 years of age. * subject must have stenosis (\>30% by visual estimate) in all 3-epicardial coronary arteries. * ffr should be measured at all 3-vessels at the end of a procedure. exclusion criteria: * depressed left ventricular systolic function (ejection fraction \< 35%) * st-elevation myocardial infarction within 72 hours, * prior coronary artery bypass graft surgery * creatinine level \>= 2.0mg/dl or dependence on dialysis * abnormal final myocardial flow (timi flow \< 3) * planned bypass surgery * failed ffr measurement * failed intended revascularization

Keywords: coronary artery atherosclerosis angina pectoris
effectiveness of the rauc pathway in reducing unscheduled hospitalizations after emergency digestive surgery

Conditions: Digestive Emergency; New Pathway; Connected Health

Summary: the number of emergencies's visits (22 million visits in 2019 in france), the organization of emergencies and the sustainability of the current health system are threatened. in the chuap adult emergency department, 60,000 visits were recorded in 2022. unlike medical emergencies which have structured their care and research activities (heart, brain), and whose organization has demonstrated its general interest for society, digestive surgical emergencies, which involve complex patients (elderly people, comorbidities) , emergency situations and surgical procedures, have never been thought of globally in terms of personalized care and research pathways. currently, patients treated in emergency are managed without a pre-established optimization program and without a dedicated pathway, where emergency constitutes a major risk factor for postoperative complications. raucamiens evaluates a new care pathway implemented within the framework of the rhu rauc : the implementation of the enhanced rehabilitation after surgery (eras) and e-health devices for home monitoring, for patients treated in the emergency room for a digestive pathology. the purpose is to evaluate the effectiveness of the rauc pathway in reducing the rate of unplanned hospitalization readmission after emergency digestive surgery 30 days postoperative.


Eligibility criteria:
inclusion criteria: * criterion linked to the protocol : -- patient consulted in emergency for a digestive pathology requiring surgery * search criteria: * adult patient (≥ 18 years old), * able to give consent, * affiliation to a social security scheme exclusion criteria: * criterion linked to the protocol: * patient leaving hospitalization to a convalescent center * patient requiring direct operating room (vital emergency or surgical revision) * patient presenting to the emergency room for a postoperative complication * patient directly admitted to intensive care * search criteria: * pregnant or breastfeeding woman * patient under guardianship, curatorship or deprived of liberty

Keywords: digestive emergency new pathway connected health
expanded access to ziftomenib

Conditions: Acute Lymphoblastic Leukemia, With Appropriate Mutations; Acute Myeloid Leukemia, With NPM1 Mutations

Summary: requests for single patient expanded access to ziftomenib monotherapy may be considered for eligible adult patients with acute lymphoblastic leukemia (all) with kmt2a rearrangements, or acute myeloid leukemia (aml), with npm1 mutations or kmt2a rearrangements. to request access, use responsible party contact information provided in this record. expanded access for ziftomenib is only available in the united states.

• subsection condition: * npm1 mutation in aml patients * kmt2a rearrangement in aml patients * kmt2a rearrangement in all patients

Eligibility criteria:
inclusion/exclusion criteria: * diagnosed with acute myeloid leukemia (aml) or acute lymphoblastic leukemia (all). * adult, ages 18+. * has exhausted appropriate standard treatments without success and no comparable or satisfactory alternative treatment is available or exists to treat the disease or condition. for newly diagnosed aml patients with either npm1-mutant, or kmt2a-rearranged aml, ziftomenib therapy will be considered for patients not eligible for ongoing clinical trials. in the case of patients with kmt2a-rearranged aml, expanded access to ziftomenib will only be provided for use in combination with fda-approved therapies currently under clinical investigation at kura oncology (e.g., venetoclax + azacitidine, cytarabine + daunorubicin). * is ineligible for participation in any ongoing clinical study of the investigational drug, which includes lack of access due to geographic limitations. * meets any other pertinent medical criteria for access to the investigational drug, as established by kura oncology.
evaluating symptom control in in allergic rhinitis at three years after starting immunotherapy

Conditions: Allergic Rhinitis

Summary: allergic rhinitis (ar) is defined as inflammation of the nasal mucosa after exposition to an allergen in sensitized patients. ar causes not only nasal symptoms such as sneezing, itchy nose, rhinorrhea and nasal obstruction, but also has a significant impact on quality of life. symptom control and overall satisfaction in patients undergoing subcutaneous immunotherapy (scit) or sublingual immunotherapy (slit) on the long term has not yet been investigated so far.


Eligibility criteria:
inclusion criteria: 1. patients with at least 2 ar symptoms and a positive skin prick test for the 20 most prevalent inhalant allergens (house dust mites, grass pollen, tree pollen, animal dander, alternaria, penicillium and cladosporium) in belgium. 2. moderate/severe and/or persistent ar according to aria guidelines 3. age \> 18 and \< 60 years. 4. written informed consent 5. dutch, french or english speaking patients exclusion criteria: exclusion criteria 1. age \ 60 years 2. patients with mild ar 3. patients not being able to give an informed consent 4. patients being enrolled in other clinical trials 5. no knowledge of dutch, french or english
prospective cohort of patients with hepatocellular carcinoma in france

Conditions: Cancer of Liver; Hepatocellular Carcinoma

Summary: hepatocellular carcinoma (hcc) occurs in 90% of cirrhosis primary liver cancers. in france, 8,500 new cases of hcc occur each year, and about 8,000 deaths per year are related to this cancer. the 5-year survival rate is 10%, one of the lowest survival rates of all cancer types. hcc raises a number of major challenges: hcc is discovered at a curable stage in only 25% of cases, reflecting the marked delay in the diagnosis of early stages. the state of knowledge about hcc is well behind that of other cancers (no biomarker, complex carcinogenesis, influence of the aetiology, poorly valorised data, etc.). rapid technological progress requires large-scale studies to evaluate new diagnostic and therapeutic modalities. the chief project constitutes a common basis knowledge for research project using prospectively collected data in patients with hcc, regardless of the cause and stage of the cancer. this project is a multicentre longitudinal observational study of patients with hcc with prospective data collection on inclusion and patient follow-up. constitution of a biological resources collection. 5,000 patients will be included over 2 years with a follow-up of patients of 5 years.


Eligibility criteria:
inclusion criteria: * new cases of hcc * suspected case of hcc regardless of the cause, stage, treatment * known hcc: drug treatment for recurrence or progression exclusion criteria: * associated serious condition threatening life in the short term (with the exception of liver disease itself) * so-called vulnerable populations: minors, persons under guardianship or temporary guardianship, or person deprived of their liberty by an administrative or judicial decision

Keywords: cancer liver hepatocellular carcinoma cohort
monosialotetrahexosylganglioside sodium injection for prevention neurotoxicity of mfolfox 6 in advanced gastric cancer

Conditions: Gastric Cancer

Summary: for gastric patients of karnofsky scores between 60-80 scores, mfolfox6 is an option for chemotherapy. neutropenia and oxaliplatin-induced neurotoxicity are the most common adverse effects which even result in discontinue of chemotherapy, especially for patients suffered from heavily acute neurotoxicity. monosialotetrahexosylganglioside is a component of membrane of nerve cells. previous phase ii clinical trial showed, it can reduce oxaliplatin-induced neurotoxicity(oin). but it did not certificated by phase iii trial. a phase iii trial is needed to investigate the effect and safety of monosialotetrahexosylganglioside sodium injection for prevention oin at gastric cancer.

it is a placebo controlled phase iii trial. investigators plan to enroll 240 patients with 1:1 to a arm and b arm

Eligibility criteria:
inclusion criteria: 1. patients shall have normal organic function such as liver function, cardiac function and renal function; 2. age \>18 years old; 3. diagnosis metastatic colorectal cancer with histology; 4. did not received first-line chemotherapy 5. karnofsky performance scores should be 60,70,or80 6. should have target lesions or non-target lesions 7. for patients received oxaliplatin before, the residual neurotoxicity should less than grade 2 8. for diabetes without neuropathy, blood glucose before meal should less than 8mmol/l and hba1c\<7.0% 9. patients should be expected to live no shorter than 3 months exclusion criteria: 1. patients who is receiving chemotherapy; 2. wbc\ 1.5limitation;bun）\>1.5limitation；cr）\>1.5limitation；alt or ast\>2.5limitation（without liver metastasis）；alt or ast）\>5limitation（with liver metastasis）; 3. heart dysfunction; 4. brain metastasis; 5. peripheral nervous system or central nervous system abnormal including diabetes mellitus patients with neuropathy; 6. patients who received glutathione, acetylcysteine, calcium / magnesium, amifostine, carbamazepine, b vitamins, vitamin e within 30 days

Keywords: metastatic gastric cancer neurotoxicity mfolfox6 monosialotetrahexosylganglioside sodium injection